Online citations, reference lists, and bibliographies.
← Back to Search

The Role Of FDG PET-CT In Differential Diagnosis Of Pleural Pathologies.

U. Elboğa, M. Yılmaz, M. Uyar, Y. Zeki Çelen, K. Bakır, O. Dikensoy
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE This study has aimed to evaluate the impact of (F18) Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) in the differential diagnosis of malignant and benign pleural lesions in patients with suspected malignant pleural mesothelioma (MPM). MATERIAL AND METHODS Fifty patients (32 females, 18 males; age range 24-79 years) with pleural thickening, fluid, plaques or calcification on previous CT scan were examined with FDG PET-CT. PET-CT imaging was obtained 1 h after FDG injection. In 12 patients, delayed imaging from the thoracic region was performed 2 h after injection. FDG uptake was evaluated visually and semiquantitively using standardized uptake value (SUV). FDG PET-CT findings were compared with histopathologic diagnosis. RESULTS Thirty-nine patients had increased FDG uptake in pleural lesions but PET-CT results were negative in 11 patients. When compared with histopathological results in FDG positive group, 34 patients had MPM, 5 had benign pathology; in FDG negative group 8 patients had benign pathology, 3 had MPM. Of patients with delayed imaging, 9 showed increased SUV but 3 had a decreased SUV on delayed images. Increased SUV group had 4 MPM, 5 benign pathology (3 chronic granulomatous inflammation, 2 benign asbestotic plaque). Decreased SUV group all had benign pathology (fibrosis, chronic inflammation, myofibrosis). DISCUSSION FDG PET-CT is a useful imaging modality in differential diagnosis of malignant and benign pleural lesions. Delayed imaging seems to be useful if there is a decrease in SUV suggesting a benign pathology but does not seem to contribute to the differential diagnosis if the SUV is increased.
This paper references
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1159/000196678
Malignant localized fibrous tumor of the pleura occurring in a person environmentally exposed to tremolite asbestos.
M. Metintas (1997)
10.1016/J.LUNGCAN.2007.09.027
Current state and future directions of pleural mesothelioma imaging.
S. Armato (2008)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1378/CHEST.125.6.2356
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1053/RMED.2001.1108
p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.
R. Işık (2001)
10.1016/J.LUNGCAN.2004.04.016
Positron emission tomography in the diagnosis of mesothelioma.
U. Haberkorn (2004)
10.1183/09031936.05.00136404
Nonmalignant pleural lesions due to environmental exposure to asbestos: a field-based, cross-sectional study
M. Metintas (2005)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/J.REMNGL.2010.08.003
[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
J. Rincón (2011)
10.1016/J.CCM.2006.02.001
Imaging of pleural disease.
N. R. Qureshi (2006)
10.1016/J.EJRAD.2007.08.010
Morphologic and functional imaging of malignant pleural mesothelioma.
M. Yamamuro (2007)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.2214/AJR.182.4.1820983
False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities.
Syed K. Asad (2004)
10.3413/NUKMED-0091
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
S. Krüger (2007)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
PET for the evaluation of pleural thickening observed on CT.
H. Kramer (2004)
10.1136/oem.45.12.838
An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.
Y. Bariş (1988)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
10.1016/J.RO.2004.04.005
Imaging evaluation in the diagnosis and staging of malignant pleural mesothelioma.
M. Truong (2004)



This paper is referenced by
10.5772/55722
Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies
K. Lau (2013)
10.5152/tcb.2015.060
Pet Applications For Staging And Restaging In Thoracic Malignancies
T. Ones (2015)
Malignant Pleural Mesothelioma and the Role of Non – Operative Therapies Kelvin
C. Ng (2018)
SAHİBİ VE SORUMLU MÜDÜR/ OWNER AND RESPONSIBLE MANAGER
Bahaüddin ÇOLAKOĞLU (2018)
10.1016/j.lungcan.2018.01.014
Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy
S. Tsim (2018)
10.1378/chest.14-0820
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
J. M. Porcel (2015)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1016/j.ejrad.2016.06.013
Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.
Katsuya Kato (2016)
10.26650/iuitfd.2019.0019
MALIGN PLEVRAL MEZOTELYOMA AYIRICI TANISI VE PROGNOZUNDA 18F-FDG PET/BT’NİN ROLÜ
D. Şimşek (2019)
10.21037/amj.2020.02.04
Malignant pleural effusion and mesothelioma
D. Subotic (2020)
10.5578/tt.67947
The F-18 FDG PET/CT and CT evaluation of pleural plaques.
Z. Koç (2019)
10.1016/j.acra.2013.09.015
Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
G. Treglia (2014)
10.1186/1471-2407-14-453
18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues
S. Povoski (2014)
Semantic Scholar Logo Some data provided by SemanticScholar